The Goldman Sachs Group Forecasts Strong Price Appreciation for Johnson & Johnson (NYSE:JNJ) Stock

Key Points

• Goldman Sachs has raised its price target for Johnson & Johnson's stock from $186.00 to $212.00, indicating a potential upside of 11.17% from its previous close of $190.71.
• Recent reports from other brokerages have also increased their price targets for Johnson & Johnson, with Citigroup setting a target as high as $213.00 and Guggenheim upgrading its rating to "buy."
• Johnson & Johnson's stock has a consensus rating of "Moderate Buy" with institutional investors owning approximately 69.55% of the company's shares, reflecting strong investor confidence.

Johnson & Johnson (NYSE:JNJ - Get Free Report) had its price objective hoisted by equities researchers at The Goldman Sachs Group from $186.00 to $212.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. The Goldman Sachs Group's target price would suggest a potential upside of 11.17% from the company's previous close.

A number of other brokerages also recently commented on JNJ. HSBC upped their target price on Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday, September 16th. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Citigroup raised their target price on Johnson & Johnson from $200.00 to $213.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Morgan Stanley lifted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $191.41.

Johnson & Johnson Trading Up 0.5%

Shares of NYSE:JNJ traded up $1.02 during trading on Thursday, hitting $190.71. 3,099,939 shares of the company's stock were exchanged, compared to its average volume of 8,890,104. The firm has a 50-day moving average price of $177.49 and a two-hundred day moving average price of $163.37. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market cap of $459.29 billion, a P/E ratio of 20.39, a PEG ratio of 2.41 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $192.10.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors have recently added to or reduced their stakes in the business. Wynn Capital LLC lifted its stake in Johnson & Johnson by 0.4% during the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company's stock worth $2,954,000 after acquiring an additional 57 shares in the last quarter. W.H. Cornerstone Investments Inc. grew its position in shares of Johnson & Johnson by 0.7% in the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company's stock worth $1,206,000 after acquiring an additional 58 shares in the last quarter. YANKCOM Partnership boosted its position in Johnson & Johnson by 0.8% during the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company's stock worth $1,076,000 after acquiring an additional 58 shares during the period. Greenup Street Wealth Management LLC raised its position in shares of Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company's stock worth $309,000 after purchasing an additional 60 shares during the period. Finally, Ellis Investment Partners LLC boosted its stake in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock worth $1,307,000 after acquiring an additional 62 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.